GSK’s Nucala Wins CHMP Nod for COPD in Europe
UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the European Medicines Agency’s Committee for...
Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio
Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) announced a definitive agreement to acquire Arthrosi Therapeutics,...
Novo Nordisk’s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity
Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s Committee for Medicinal Products...
Innovent’s Mazdutide Wins Macau Approval for Weight Management
Innovent Biologics, Inc. (HKG: 1801) announced that mazdutide received marketing approval from Macau’s drug regulatory...
Cellular Origins Raises $40M Series A Led by Johnson & Johnson for Cell Therapy Manufacturing
Cellular Origins announced the completion of an over‑subscribed $40 million Series A financing round led by...
Akeso’s Cadonilimab Wins FDA Nod for Global Phase 3 Gastric Cancer Study
Akeso Biopharma (HKG: 9926) announced that the U.S. FDA approved cadonilimab in combination with chemotherapy...
China Healthcare Fund Settlement Reform Targets 3% Ratio by 2028
The National Healthcare Security Administration (NHSA) released a notice to optimize healthcare fund settlement management,...
Junshi Biosciences Wins FDA Nod for EGFR/HER3 Bispecific ADC in Solid Tumors
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and...
Henlius Serplulimab NDA Wins Priority Review for Gastric Cancer as Adjuvant Therapy
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the NMPA accepted its New Drug Application...
Hanx Biopharma Prices HKEX IPO to Fund Bispecific Antibody Pipeline
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. released its prospectus for a Hong Kong Stock Exchange listing...
China Unveils Elderly Nursing Plan to Boost 90% Nurse Coverage by 2027
China’s National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Administration of Traditional Chinese...
Amgen’s Uplizna Scores Third FDA Indication in Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the U.S. FDA approved Uplizna (inebilizumab-cdon) for adult patients...
Huadao Submits China CAR‑T Application for Refractory Lymphoma in $1B Market
Suzhou Huadao Biological Pharmacy Co., Ltd. officially submitted a Marketing Authorization Application (MAA) to the...
Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation
Peijia Medical Limited (HKG: 9996) announced that China’s National Medical Products Administration (NMPA) approved the...
Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal
Hasten Biopharmaceutical Co., Ltd. and Everest Medicines Limited (HKG: 1952) announced two strategic agreements: a...
Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial
Eli Lilly & Co. (NYSE: LLY) announced positive topline results from the Phase 3 TRIUMPH‑4...
Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment
Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that its Class 1 innovative drug, Pixavir...
InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program
InduPro Therapeutics, a biotechnology company defining membrane protein spatial relationships for novel therapeutics, announced a...
InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor
InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self‑developed next‑generation TRK inhibitor, Zurletrectinib...